In Brief: revised NDI draft expected in 2013, MusclePharm invests, Sundial label and GMP warnings, AHPA publishes organic guidance
This article was originally published in The Tan Sheet
Executive Summary
CFSAN plans revised NDI draft in 2013; MusclePharm invests in BioZone delivery tech; Indiana kicks off anti-smurfing campaign; Sundial fails basic labeling, GMP compliance; AHPA advises supplement firms on organic rules; Naturex commits to sustainability; Targeted Medical Pharma expands into supplements.